DGAP-Adhoc: Not for distribution in or into the United States, Canada, Japan or Australia - MediClin has resolved upon a capital increase by utilization of authorized capital at the ratio of 2:1 at a subscription price per share of € 2.50

| Source: EQS Group AG EQS Group AG 

MediClin AG / Capital Increase

21.11.2008 

Release of a Adhoc News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------

Frankfurt am Main, November 21, 2008 – The management board of MediClin
Aktiengesellschaft, with the consent of the supervisory board, resolved
today to increase the share capital via authorized capital from €
31,500,000.00 by € 15,750,000.00 to € 47,250,000.00 by issuing 15,750,000
new ordinary bearer shares with no par value (no par value shares), each
share with a notional par value of € 1.00 and full dividend rights as of
January 1, 2008, against cash contribution. ERGO Versicherungsgruppe
Aktiengesellschaft and DKV Deutsche Krankenversicherung AG have obligated
themselves to the MediClin Aktiengesellschaft to directly subscribe for the
new shares underlying their subscription rights. The Landesbank
Baden-Württemberg will subscribe for the remaining new shares with the
obligation to offer these new shares for sale to shareholders by way of an
indirect subscription right.

The new shares will be offered to the company's shareholders for
subscription at the ratio of 2:1, i. e., 2 subscription rights will entitle
the holder to subscribe for 1 new share. The subscription price per share
will be € 2.50.

New shares that are not subscribed for in the rights offering will be
offered through private placements to qualified investors outside of the
United States on the basis of Regulation S under the U. S. Securities Act
of 1933, as amended, as well as outside of Canada, Japan and Australia, at
the subscription price.

ERGO Versicherungsgruppe Aktiengesellschaft has obligated itself to
purchase at the subscription price those shares not placed through the
private placements.

Important Information
This publication constitutes neither an offer to sell nor a solicitation of
an offer to buy any securities. An offer will be made solely by means, and
on the basis, of a prospectus to be published prior to any offering of
securities of MediClin Aktiengesellschaft, which will be available free of
charge at MediClin Aktiengesellschaft, Okenstr. 27, 77652 Offenburg, and at
Landesbank Baden-Württemberg, Hauptbahnhof 2, 70173 Stuttgart. This
publication and the information contained herein are not for distribution
in or into the United States of America and must not be distributed to
publications with a general circulation in the United States. The
securities of MediClin Aktiengesellschaft have not been registered under
the U. S. Securities Act of 1933, as amended, ('Securities Act') and may
not be offered, sold or delivered within the United States absent
registration or an exemption from the registration requirements of the
Securities Act. There will be no public offering of securities in the
United States. This publication is directed only at persons (I) who are
outside the United Kingdom or (II) who have professional experience in
matters relating to investments falling within Article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005
(as amended) (the 'Order') or (III) who fall within Article 49(2)(A) to (D)
('High Net Worth Companies, Unincorporated Associations etc.') of the Order
(all such persons being together referred to as 'relevant persons'). Any
person who is not a relevant person must not act or rely on this
publication or any of its contents. Any investment or investment activity
to which this publication relates is available only to relevant persons and
will be engaged in only with relevant persons.
DGAP 21.11.2008 
---------------------------------------------------------------------------
Language:     English
Issuer:       MediClin AG
              c/o MediClin Geschäftsführungs-GmbH Okenstraße 27
              60329 Frankfurt
              Deutschland
Phone:        +49 (0)781 488-189
Fax:          +49 (0)781 488-184
E-mail:       alexandra.muehr@mediclin.de
Internet:     www.mediclin.de
ISIN:         DE0006595101
WKN:          659510
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News                                     DGAP News-Service
---------------------------------------------------------------------------